2 results
Approved WMOCompleted
Primary Objective To determine whether the combination of Onartuzumab + * erlotinib is superior (in terms of OS) to placebo * erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic*positive non*small cell lung cancer (…
Approved WMOPending
The primary, secondary and exploratory objectives of the study are as follows:Part APrimary:• To evaluate the safety and tolerability of the different GEH200520 Injection mass doses and a fixed dose of GEH200521 (18F) Injection when administered…